Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04278781 · ClinicalTrials.gov registry record · Phase 2
AG-120 in People With IDH1 Mutant Chondrosarcoma
A Phase 2 study of Chondrosarcoma and IDH1 Gene Mutation, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 5
- Study locations
NCT04278781: Active Phase 2 study of Chondrosarcoma and IDH1 Gene Mutation, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04278781 is a Phase 2 study of Chondrosarcoma and IDH1 Gene Mutation that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 6 participants, below the 128-participant average among 11 other Chondrosarcoma trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04278781, a Phase 2 study of Chondrosarcoma and IDH1 Gene Mutation, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.
Primary Outcome
Progression free survival includes both disease progression (as defined by RECIST 1.1) and death from any cause
Conditions Studied
Interventions
- DRUG AG-120
Study Locations (5)
New York
- Columbia University (Specimen Analysis Only) - New York
- Memorial Sloan Kettering Cancer Center - New York
Maryland
- Johns Hopkins Hospital (Data Collection Only) - Baltimore
Ohio
- The Ohio State University (Data Collection Only) - Columbus
Texas
- MD Anderson Cancer Center (Data Collection Only) - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-03-04 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
What the registry record for NCT04278781 still lists
NCT04278781 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 128-participant average among 11 other Chondrosarcoma trials with a reported enrollment target (95% lower).
The record links to 4 conditions, with Chondrosarcoma appearing as the primary indexed condition, and to 1 intervention - of which AG-120 is the first listed.
NCT04278781 lists 5 locations in 4 states (New York, Maryland, Ohio).
Frequently Asked Questions
What is clinical trial NCT04278781 about?
NCT04278781 is a clinical study titled "AG-120 in People With IDH1 Mutant Chondrosarcoma". This study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.
What is the current status of trial NCT04278781?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2020-03-04. Estimated completion is 2026-03.
What conditions does trial NCT04278781 study?
This clinical trial studies the following conditions: Chondrosarcoma, IDH1 Gene Mutation, Chondrosarcoma, Grade 2, Chondrosarcoma, Grade 3.
What interventions are being tested in trial NCT04278781?
The interventions under investigation include: AG-120 (DRUG).
Who is sponsoring clinical trial NCT04278781?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04278781 being conducted?
This trial has 5 study locations across Maryland, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chondrosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04278781's enrollment target sits among peer trials
6 12th of 11 the lowest of 11 other Chondrosarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chondrosarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
RECRUITING · Phase 2
-
Proton Beam Therapy for Chondrosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
-
Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI